The ultrasound-guided breast biopsy market is projected to grow from USD 907.0 million in 2025 to USD 1,958.1 million by 2035, at a CAGR of 8.0%. Core needle (CN) ultrasound-guided breast biopsy will dominate with a 49.6% market share, while hospitals will lead the end user segment with a 52.3% share.